Head & Neck Cancers

Here is your guide to all therapeutic options that were cleared by the FDA in June 2025 spanning tumor types.

Ravindra Uppaluri, MD, PhD, discusses the FDA approval of pembrolizumab in the neoadjuvant and adjuvant setting for resectable, locally advanced HNSCC.

Experts in the fields of lung, head and neck, HER2+ breast, and hematologic cancers discuss notable updates for fellows from the 2025 AACR Annual Meeting.

OncLive® showcases 13 cancer care pioneers, who have won the 2025 Giants of Cancer Care award.

The FDA has approved new options in head and neck cancer, lung cancer, and bladder cancer—and more from OncLive this week.

Douglas R. Adkins, MD, discusses the FDA approval of pembrolizumab for neoadjuvant and adjuvant treatment in resectable, locally advanced head and neck squamous cell carcinoma.

The FDA has approved perioperative pembrolizumab adjuvant radiotherapy in resectable locally advanced HNSCC.

Patients with locally advanced, high-risk head and neck cancer showed significantly improved DFS with adjuvant nivolumab plus cisplatin and radiotherapy.

The EMA’s CHMP recommended the EU approval of first-line tislelizumab plus chemotherapy for adults with recurrent or metastatic nasopharyngeal carcinoma.

Aditya Shreenivas, MD, MS, discusses the FDA approval of penpulimab for recurrent/metastatic non-keratinizing NPC.

OncLive announces the inductees of the 13th annual Giants of Cancer Care recognition program.

Treatment with eftilagimod alpha plus pembrolizumab produced a median OS of 17.6 months in the first line for patients with PD-L1–negative HNSCC.

Glenn J. Hanna, MD, discusses the efficacy of elraglusib plus chemotherapy with or without immunotherapy in patients with advanced salivary gland cancer.

Perioperative pembrolizumab with postoperative radiation with or without cisplatin showed durable EFS in resectable, locally advanced HNSCC.

The FDA has approved penpulimab for select patients with non-keratinizing nasopharyngeal carcinoma.

Zafar Sayed, MD, explains advances in surgical head and neck cancer approaches, including the use of transoral robotic surgery.

Akina Tamaki, MD, highlights treatment considerations, the therapeutic arsenal, and surgical advancements in head and neck cancer.

Akina Tamaki, MD, highlights treatment considerations, the therapeutic arsenal, and surgical advancements in head and neck cancer.

Here is your Q2 2025 preview spotlighting 7 FDA decisions to watch, including upcoming PDUFAs for nivolumab/ipilimumab, belzutifan, UGN-102, avutometinib/defactinib, and more.

Penpulimab received NMPA approval for first-line use with chemotherapy in recurrent or metastatic nasopharyngeal carcinoma.

All the data on the tumor-agnostic approvals of T-DXd and repotrectinib are featured in this article and it's downloadable PDF visual pages!

AVA6000 showed early efficacy and safety signals in previously treated, locally advanced or metastatic salivary gland cancers.

MT-8421, a novel engineered toxin body targeting CTLA-4, was not associated with grade 4 or 5 toxicities in patients with select advanced solid tumors.

Versamune HPV plus PDS01ADC and bintrafusp alfa demonstrated clinical benefit in locally advanced or metastatic HPV-associated cancers.

Perioperative pembrolizumab sBLA gets priority review in HNSCC, nivolumab/ipilimumab sBLA in MSI-H/dMMR CRC is under review, and more from OncLive this week.